Skip to main content
SpringerLink
Log in

Refractory Idiopathic Immune Thrombocytopenic Purpura in Children

Current and Future Treatment Options

  • Therapy In Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

A minority of children with idiopathic or immune thrombocytopenic purpura (ITP) have the refractory chronic form with bleeding problems (stage III or IV). The aim of this article is to provide an update on the immunopathogenesis and management of children with bleeding and severe refractory ITP. The management of such patients, according to a staging guideline, is described.

Recent clinical and laboratory observations document the disturbed immune responses that occur on various levels in chronic ITP. New therapeutic options are directed towards influencing these immunopathogenic mechanisms.

Because ITP is not adequately defined and has heterogeneous manifestations, today’s management recommendations are largely opinion-based rather than evidence-based. In severe refractory childhood ITP, consensus between the treating physician and the patient has to be achieved on an individual basis. The aim is to maintain the disease at stages I or II, with minimal intervention, and to prevent bleeding. If bleeding is not under control, medical treatment (as described in this article), or splenectomy, has to be considered.

Although there is a paucity of data relating to children, potential new treatment options for refractory ITP include strategies aimed at influencing antigenemia, the T cell immune response (e.g. cyclosporine, CTLA-4-Ig) or the B-cell immune response (e.g. anti-CD20 monoclonal antibody, anti-CD52 monoclonal antibody, interferon).

New prospective, cooperative ITP registries have been created to search for subgroups with different severities of ITP, which will be the selection criteria of future controlled studies in pediatric patients with refractory ITP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Imbach P. Immune thrombocytopenic purpura. In: Lilleyman JS, Hann IM, Blanchette VS, editors. Pediatric hematology. 2nd ed. London: Churchill Livingstone, 1999

    Google Scholar 

  2. Lilleymann JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999; 71: 251–3

    Google Scholar 

  3. Kühne T, Imbach P, Bolton-Maggs PHB, et al., for the Intercontinental Childhood FTP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001; 358: 2122–5

    Article  PubMed  Google Scholar 

  4. Imbach P, Akatsuka J, Blanchette V, et al. Immunothrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Eur J Pediatr 1995; 154(3): 60–4

    Article  Google Scholar 

  5. Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38: 433–69

    PubMed  CAS  Google Scholar 

  6. Imbach P, Barandun S, D’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; I: 1228–31

    Article  Google Scholar 

  7. Salama A, Kiefel V, Amberg R, et al. Treatment of autoimmune thrombocytopenic purpura with Rhesus antibodies (anti Rho[D]). Blut 1984; 49: 29–35

    Article  PubMed  CAS  Google Scholar 

  8. Imbach P, Kühne T, Holländer G. Immunologic aspects in pathogenesis and treatment of immune thrombocytopenic purpura (ITP) in children. Curr Opin Pediatr 1997; 9: 35–40

    Article  PubMed  CAS  Google Scholar 

  9. Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 9–12

    Article  PubMed  CAS  Google Scholar 

  10. Coopamah MD, Garvey MB, Freedman J, et al. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003; 17: 69–80

    Article  PubMed  Google Scholar 

  11. Mouzaki A, Theodoropoulou M, Gianakopoulos I, et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002; 100: 1774–9

    PubMed  CAS  Google Scholar 

  12. Trotter JL. Serial studies of serum interleukin-2 in chronic progressive multiple sclerosis patients: occurrence of bursts and effects of cyclosporine. J Neuroimmunol 1990; 28(1): 9–14

    Article  PubMed  CAS  Google Scholar 

  13. Tebib JG, Boughaba H, Letroublon MC. Serum IL-2 level in rheumatoid arthritis: correlation with joint destruction and disease progression. Eur Cytokine Netw 1991; 2: 239–43

    PubMed  CAS  Google Scholar 

  14. Huang Y-P, Perrin LH, Miescher PA, et al. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1991; 141: 827–33

    Google Scholar 

  15. DeFrance T, Vanbervliet B, Briere F, et al. Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin. A J Exp Med 1992; 175: 671–82

    Article  CAS  Google Scholar 

  16. Howard M, Muchamuel T, Audrade S, et al. Anti-inflammatory effect of IL-10. J Exp Med 1993; 177: 1205–8

    Article  PubMed  CAS  Google Scholar 

  17. Nepom G, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol 1991; 9: 493–525

    Article  PubMed  CAS  Google Scholar 

  18. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88(1): 3–40

    PubMed  CAS  Google Scholar 

  19. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574–96

    Article  Google Scholar 

  20. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989; 74: 2309–17

    PubMed  CAS  Google Scholar 

  21. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008

    Article  PubMed  Google Scholar 

  22. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330: 1560–4

    Article  PubMed  CAS  Google Scholar 

  23. Yoshida K, Yamazaki Y, Mizuno R, et al. Laparoscopic splenectomy in children: preliminary result and comparison with the open technique. Surg Endose 1995; 9: 1279–82

    Article  CAS  Google Scholar 

  24. Cahill MR, Macey MG, Cavenagh JD, et al. Protein A immunoadsorption in chronic refractory ITP reverses increased platelet activation but fails to achieve sustained clinical benefit. Br J Haematol 1998; 100: 358–64

    Article  PubMed  CAS  Google Scholar 

  25. Snyder HW, Cochran SK, Balint JP, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992; 79: 2237–45

    PubMed  Google Scholar 

  26. Meeker ND, Goldsby R, Terrill KR, et al. Dapsone therapy for children with immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25: 173–5

    Article  PubMed  Google Scholar 

  27. Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori [letter]. Lancet 1998; 352: 878

    Article  PubMed  CAS  Google Scholar 

  28. Emilia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97: 812–4

    Article  PubMed  CAS  Google Scholar 

  29. Ellaurie M, Burns E, Bernstein L, et al. Thrombocytopenia and human immunodeficiency virus in children. Pediatrics 1988; 82: 905–8

    PubMed  CAS  Google Scholar 

  30. Imbach P, Luginbühl L, Späth P, et al. Cyclosporin A (CyA) and intravenous immunoglobulin (i.v. IgG) in chronic immune thrombocytopenic purpura (ITP) in childhood: a clinical and immunological study (progress report). In: Schindler R, editor. Cyclosporin in autoimmune disease. Berlin: Springer Verlag, 1985: 268–9

    Chapter  Google Scholar 

  31. Kappers-Klunne MC, van’t Veer MB. Cyclosporin A for the treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 2001; 114: 121–5

    Article  PubMed  CAS  Google Scholar 

  32. Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood 2002; 99: 1482–5

    Article  PubMed  CAS  Google Scholar 

  33. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243–52

    Article  PubMed  CAS  Google Scholar 

  34. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–45

    PubMed  CAS  Google Scholar 

  35. Stasi R, Pagana A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952–7

    Article  PubMed  CAS  Google Scholar 

  36. Cooper N, Stasi R, Feuerstein M, et al. Transient B cell depletion with rituximab, an anti CD20 monoclonal antibody, resulted in lasting complete responses in 16 of 57 adults with refractory immune thrombocytopenic purpura [abstract no. 187]. American Society of Hematology 44th Annual Meeting; 2002 Dec 6–10; Philadelphia

  37. Giagounidis AAN, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002; 69: 95–100

    Article  PubMed  CAS  Google Scholar 

  38. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 189–95

    PubMed  CAS  Google Scholar 

  39. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 6Suppl. 12: 99–103

    Google Scholar 

  40. Delgado J. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 2002; 87: 215–6

    PubMed  Google Scholar 

  41. Monroy RH, Viveros PV, Violante MR. Effect of anti-CD20 (rituximab) in refractory immune thrombocytopenic purpura (RITP): report of three new cases [abstract no. 3797]. American Society of Hematology 44th Annual Meeting; 2002 Dec 6–10; Philadelphia

  42. Rosenthal E, Karsenti JM, Pesce A, et al. Anti-CD20 monoclonal antibody (rituximab) administration in patients with refractory immunologic thrombocytopenic purpura [abstract no. 2194]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7–11; Orlando

  43. Schuler US, Florek M, Mueller J, et al. Successful rituximab treatment of immune thrombocytopenia (FTP) in an elderly lady with systemic mastocytosis [abstract no. 3875]. American Society of Hematology 43rd Annual Meeting; 2001 Dec 7–11; Orlando

  44. Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia: case report. Eur J Haematol 2001; 66: 408–11

    Article  PubMed  CAS  Google Scholar 

  45. Shvidel L, Klepfish A, Berrebi A. Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-hodgkin’s lymphoma. Am J Hematol 2001; 67: 213–9

    Article  PubMed  CAS  Google Scholar 

  46. Patel K, Berman J, Ferber A, et al. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol 2001; 67: 59–60

    Article  PubMed  CAS  Google Scholar 

  47. Hedge UP, Wilson WH, White T, et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100(6): 2260–2

    Google Scholar 

  48. Heelan BT, Tormey V, Amlot P, et al. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol 2002; 118: 1078–81

    Article  PubMed  Google Scholar 

  49. Gilleece MH, Dexter TM. Effect of compath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807–12

    PubMed  CAS  Google Scholar 

  50. Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1995; 1: 175–87

    Article  PubMed  CAS  Google Scholar 

  51. Mathieson PW, Cobbold SP, Hale G, et al. Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med 1990; 323: 250–4

    Article  PubMed  CAS  Google Scholar 

  52. Lockwood CM. Refractory Wegener’s granulomatosis: a model for shorter immunotherapy of autoimmune diseases. J R Coll Physicians Lond 1998; 32: 473–8

    PubMed  CAS  Google Scholar 

  53. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Compath-1H in patients with autoimmune cytopenias. Br J Haematol 2001; 114: 891–8

    Article  PubMed  CAS  Google Scholar 

  54. Proctor SJ, Jackson G, Carey P, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon. Blood 1989; 74: 1894–7

    PubMed  CAS  Google Scholar 

  55. Hrstkova H, Bajer M, Michalek J. Recombinant human interferon alpha-2a therapy in children with chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2002; 24: 299–303

    Article  PubMed  Google Scholar 

  56. Rice L, Nichol JL, McMillan R. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Haematol 2001; 68: 210–4

    Article  CAS  Google Scholar 

  57. Huhn RD, Read EJ, Rick M, et al. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia [abstract]. Blood 1999; 94: 178

    Google Scholar 

  58. ICIS Intercontinental Childhood ITP Study Group [online]. Available from URL: http://www.unibas.ch/itpbasel [Accessed 2003 Oct 29]

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Oncology/Hematology, University Children’s Hospital (UKBB), Rōmergasse, Basel, CH-4005, Switzerland

    Paul Imbach

Authors
  1. Paul Imbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Imbach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Imbach, P. Refractory Idiopathic Immune Thrombocytopenic Purpura in Children. Pediatr-Drugs 5, 795–801 (2003). https://doi.org/10.2165/00148581-200305120-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200305120-00003

Keywords

Search

Navigation